Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) EPS (Weighted Average and Diluted) (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed EPS (Weighted Average and Diluted) for 3 consecutive years, with -$0.26 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, EPS (Weighted Average and Diluted) fell 178.79% year-over-year to -$0.26, compared with a TTM value of -$0.48 through Dec 2024, down 442.86%, and an annual FY2024 reading of -$0.48, down 442.86% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.26 for Q4 2024 at Oramed Pharmaceuticals, up from -$0.48 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.33 in Q4 2023 and bottomed at -$0.48 in Q3 2024.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$0.11, with a median of -$0.13 recorded in 2022.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 833.33% in 2024, while the deepest fall reached 500.0% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.3 in 2022, then surged by 210.3% to $0.33 in 2023, then crashed by 178.79% to -$0.26 in 2024.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ORMP at -$0.26 in Q4 2024, -$0.48 in Q3 2024, and $0.22 in Q2 2024.